Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

13.03
-0.0374-0.29%
Volume:423.43K
Turnover:5.45M
Market Cap:997.24M
PE:-9.06
High:13.13
Open:13.02
Low:12.63
Close:13.07
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.70
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:7.91
PE(LYR):-18.08

Loading ...

Candel Therapeutics Inc: Phase 3 Pivotal Study Planned for Initiation in Q2 2026

THOMSON REUTERS
·
Mar 17

Candel Therapeutics Inc: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec

THOMSON REUTERS
·
Mar 17

Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial

Reuters
·
Mar 17

Candel Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk

TIPRANKS
·
Mar 13

Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate

Benzinga Earnings
·
Mar 12

Candel Therapeutics Q4 operating loss misses analyst expectations

Reuters
·
Mar 12

BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million

Reuters
·
Mar 12

Candel Therapeutics Q4 Income From Operations USD -15.752 Million VS. Ibes Estimate USD -13.9 Million

THOMSON REUTERS
·
Mar 12

Candel Therapeutics Q4 Basic EPS USD -0.54

THOMSON REUTERS
·
Mar 12

Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Dow Jones
·
Mar 12

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

GlobeNewswire
·
Mar 09

Candel Therapeutics Grants New Hire Options for 20,000 Shares Under 2025 Inducement Plan

Reuters
·
Mar 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 03